Rahul Banerjee: Dexamethasone 40mg weekly in Multiple Myeloma induction

Rahul Banerjee shared his recent article on X:

“Grateful to Blood Journal, co-authors, and SWOG Cancer Research Network for making this down with dex piece possible!

Dexamethasone 40mg weekly in Multiple Myeloma induction: Not practical even for trial-enrolled patients. Does not improve PFS vs  dex Twitter once I’m back from IMS24!”

Urvi Shah, Oncologist, Memorial Sloan Kettering Cancer Center reshared the post, adding:

“Such important data and helpful for patients! Sometimes less is more or equal too!

Congratulations Rahul Banerjee!”

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Authors: Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar,  Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering and Robert Z Orlowski.

Source: Urvi Shah/X and Rahul Banerjee/X

Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency from the University of Pennsylvania health system. He completed his fellowship in haematology and oncology from University of California, San Francisco. He has authored over 70-peer reviewed publications. His clinical interests include multiple myeloma.